10.4.2024 16:30:01 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state

Thor Medical ASA will hold its Annual General Meeting (AGM) tomorrow at 14:00
hours CEST, located at Advokatfirmaet Selmer, Ruseløkkveien 14, 0251 Oslo.
Following the AGM, CEO Alf Bjørseth will deliver a presentation providing an
update of Thor Medical's go-to-market strategy.

The company aspires to emerge as a top-tier supplier of Th-228 to the
radiopharmaceutical market and is progressing well in all aspects of the value
chain, including the scheduled launch of the pilot plant during the second half
of 2024.

With customers advancing in clinical trials and expressing interest in volume
deliveries already in 2024 and 2025, Thor Medical is looking at opportunities to
fast-track commercial volumes to the market by the end of 2025, with lower
volumes but also significantly reduced capex requirements compared with a
full-scale industrial plant.

Investment decisions for establishing commercial scale production facilities
will as previously communicated be subject to successful start-up of the pilot
plant, production of customer samples and conversion of customer LOIs into sales
agreements, and completion of an engineering study.

The presentation can be followed through a live webcast tomorrow at 15:00 (or
latest as soon as the AGM is completed) from the following link: CEO
presentation -
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20240411_2

Please find the presentation attached, which will also be uploaded to 
www.thormedical.no - http://www.thormedical.no.

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.

CONTACTS

 * Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
   brede.ellingseter@thormedical.no 

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visitwww.thormedical.no - https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/3011/4292/Download%20announcement
%20as%20PDF.pdf

CEO presentation AGM 2024.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/3011/4289/CEO%20presentation%20AG
M%202024.pdf